SEARCH RESULT

Thursday, May 27, 2021
Zoetis launches porcine circovirus vaccine
Zoetis has launched CircoMax Myco, a vaccine that includes two porcine circovirus type two (PCV2) genotypes (a and b), providing broader coverage against PCV2 and protection against two key pathogens - PCV2 and Mycoplasma hyopneumoniae - in ...
Friday, January 22, 2021
Zoetis US introduces new HVT-IBD vaccine
In a press statement, Zoetis US has expanded its line of recombinant vector vaccines with the launch of Poulvac® Procerta™ HVT-IBD, which provides early protection against the contemporary infectious bursal disease (IBD) viruses, ...
Monday, December 21, 2020
Zoetis supports US pork-based hunger relief programme with US$25,000 donation
A programme, called "Pass the Pork", had started in late April to generate pork donations to needy residents in Iowa, the United States, and is getting support from Zoetis which is donating US$25,000.
Monday, December 14, 2020
Zoetis appoints new member to board of directors
Zoetis Inc. has announced on December 8 the appointment of Antoinette (Tonie) Leatherberry, an experienced technology strategist and executive, to its board of directors.
Thursday, November 19, 2020
Zoetis supports call for greater awareness of responsible antibiotic use
Zoetis Inc. has pledged on November 19 its support for World Antimicrobial Awareness Week 2020, an initiative to encourage the prudent use of antibiotics in people and animals.
Tuesday, November 17, 2020
Zoetis first animal health company to issue review based on leading sustainability frameworks
Zoetis announced on November 16 the publication of its 2019 Environmental, Social and Governance (ESG) Review, providing more information on its ESG initiatives, including disclosures on energy, waste and workforce metrics.
Thursday, July 9, 2020
Trianni, Zoetis announce agreement to develop transgenic antibody discovery platform for use in animal health
Trianni, Inc. and Zoetis have announced on July 7 a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments.
Thursday, July 9, 2020
Zoetis acquires Fish Vet Group to enhance aquaculture diagnostic capabilities
Zoetis announced in early-July the acquisition of Fish Vet Group from Benchmark Holdings, PLC, as a strategic addition to its Pharmaq business which develops and commercialises fish vaccines and offers services in vaccination and diagnostic ...
Tuesday, June 16, 2020
Zoetis initiative drives sustainable livestock production in sub-Saharan Africa
In its third year, Zoetis' African Livestock Productivity and Health Advancement (ALPHA) initiative, co-funded with a US$14 million grant from the Bill & Melinda Gates Foundation, continues to improve livestock health and positively imp ...
Friday, November 1, 2019
Zoetis completes acquisition of vet reference lab Phoenix Lab
Zoetis Inc. announced October 31 the completion of the acquisition of Phoenix Central Laboratory for Veterinarians, Inc. (Phoenix Lab), a full-service veterinary reference laboratory company, after fulfilling all closing requirements.
Wednesday, October 30, 2019
Zoetis establishes research facility to develop vaccines for transboundary, emerging diseases in animals
Zoetis has signed an agreement with Texas A&M University's Health Science Center for Innovation in Advanced Development and Manufacturing (CIADM) to establish a facility for accelerating the development of transboundary and emerging dis ...
Tuesday, October 22, 2019
Zoetis refurbishes US site for vaccine production
No Abstract
Monday, October 24, 2016
WVPA-Zoetis Young Poultry Veterinarian of 2016 announced by WVPA
No Abstract
Friday, May 6, 2016
Zoetis, University of Surrey launch innovation center for animal health
Zoetis and the University of Surrey (England, UK) launched the Veterinary Health Innovation Engine (vHive), a novel multi-disciplinary centre designed to promote the development and adoption of digital innovation in animal health.
Friday, March 11, 2016
Zoetis launches CLARIFIDE Plus
No Abstract

Follow Us

FacebookTwitterLinkedIn